NHS England now plays a key market access gatekeeper role for the industry’s high cost specialised medicines, and has become increasingly commercially savvy over the last few years, working alongside cost effectiveness watchdog NICE.
Late last year, NHS England went one step further to develop its pricing and reimbursement expertise and appointed Blake Dark, an experienced pharma industry executive, as the new head of its commercial medicines division.
Read the full PMLive article here